Please login to the form below

Not currently logged in
Email:
Password:

GSK launches first-in-class epilepsy drug

GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures

GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the adjunct treatment of adults with partial-onset seizures, and demonstrated significant effects in a treatment resistant patient population.

Retigabine is the first AED to target neuronal potassium channels, which are involved in inhibitory mechanisms in the brain. Inhibitory mechanisms are thought to have a role in seizure control.

Professor Martin J Brodie, director of the epilepsy unit at Western Infirmary, Glasgow, UK, said: "Trobalt represents a positive addition to the therapeutic armamentarium for the many adult patients with inadequately-controlled focal onset seizures."

The efficacy and safety of retigabine was established in two pivotal multicentre, randomised, double-blind, placebo-controlled, fixed dose studies where patients who were treatment resistant were recruited. Retigabine significantly improved seizure control, with a greater number of patients achieving a reduction in the number of seizures by 50 per or more, compared with placebo.

Retigabine, referred to as ezogabine in the US, is being jointly developed by GSK and Valeant.

17th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Peter Jackson
The global antibiotic crisis: a 2020 perspective
A report from the CDC says the ‘approaching’ post-antibiotic era is already here...
Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...

Infographics